Autolus posts about $45 million in preliminary Q2 2026 AUCATZYL revenue and lines up up to $250 million Perceptive credit facility
AI Market Summary
Autolus reported preliminary Q2 2026 AUCATZYL net revenue of about $45m with ~35% YTD gross margin, raised FY2026 sales guidance to $140"150m, and secured a five-year interest-only senior credit facility up to $250m (with $75m funded at close). The update signals improving commercialization and liquidity, while the warrant issuance and milestone-based tranches may influence financing-related positioning.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT-0.44%
AI Insight · NCCOGOLD2USD/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Autolus Therapeutics said preliminary second-quarter 2026 net product revenue for AUCATZYL was about $45 million, with a year-to-date gross margin of roughly 35%. The company raised its FY 2026 sales guidance to $140–$150 million. It also announced a five-year credit facility with Perceptive Advisors of up to $250 million, with an initial $75 million funded. The update reflects stronger commercialization of its core product and improved cash-flow conditions.
